What is the ESG Strategy Specialized for the Pharmaceutical Bio Industry?…Korea Pharmaceutical Bio Association to Hold Seminar on the 28th

[Asia Economy Reporter Lee Gwan-joo] The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on the 13th that it will hold a seminar titled 'Pharmaceutical Bio-Pharma and ESG' on the 28th.

In this seminar, the association plans to enhance the awareness of ESG (Environmental, Social, and Governance) among domestic pharmaceutical bio-pharma companies and share concrete information related to investment and overseas expansion from the perspective of industry practitioners considering implementation measures.

In particular, at the level of top executives of pharmaceutical bio-pharma companies, the seminar aims to provide an understanding of 'Why ESG?' and motivate ESG management by presenting the benefits gained from adopting ESG and the benchmarks required by the international community for sustainable management.

In addition to this seminar, the association plans to conduct in-depth surveys and research on member companies through a 'Pharmaceutical Bio-Pharma and ESG' research project starting in the second half of the year, and publish a 'Pharmaceutical Bio-Pharma ESG Report' including the results.

An association official said, "Although there has been much interest and discussion across all domestic industries following the global trend of ESG management expansion, there has been a lack of opportunities to present directions for ESG activation specialized for pharmaceutical bio-pharma companies and to provide motivation for implementation. The association will make various efforts to specifically identify ESG-related issues closely linked to the industry and to provide practical support for member companies to establish and practice ESG management."

This content was produced with the assistance of AI translation services.